Scroll Top

Bringing Practical tools to patients

Welcome to the Oncoscreen Patient Portal

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur posuere sapien dolor, sed vestibulum augue consectetur sed. Morbi congue rutrum ipsum, fringilla convallis dui placerat nec. Ut in est odio. Ut efficitur ipsum at turpis sodales hendrerit. Integer sed sapien quis justo sollicitudin euismod vitae quis ante. Donec tristique viverra pellentesque. Nulla quis ornare sapien. Fusce volutpat dui dignissim tempor volutpat. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Praesent nisl lacus, mollis nec nunc ut, malesuada efficitur eros. Nunc eget vestibulum elit. Nullam ultricies eget orci ut aliquet. Nunc sed magna vitae eros dapibus finibus. Cras vel sollicitudin mi. Fusce lobortis, nisi vitae tempor interdum, est leo porttitor ante, a malesuada est ligula at nulla. Maecenas consequat malesuada ligula vitae luctus. Aenean sapien turpis, consequat eget odio eget, porta mattis est. Aenean eu lectus urna.

Pellentesque cursus dolor ac egestas elementum. In fermentum gravida neque et mattis. Praesent rhoncus leo id ligula eleifend, eu fringilla ex facilisis. Donec mi lacus, laoreet id enim a, porta cursus orci. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Praesent at nisi ut sapien consectetur mattis. Pellentesque vitae rhoncus elit, ac rutrum lectus. Mauris laoreet felis a vulputate venenatis. Mauris tempus, dui eget sollicitudin pharetra, turpis neque placerat elit, eget condimentum neque massa et ex. Maecenas quis massa a nunc lobortis facilisis. Fusce luctus in risus a varius. Nulla facilisi. Proin tempus vitae quam id bibendum. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. In volutpat venenatis tortor eget blandit. Praesent massa elit, lacinia vel finibus vel, tincidunt at urna.

Praesent pharetra turpis ut metus molestie consequat. In quis aliquet ante, ut aliquet enim. Maecenas interdum nisl non leo placerat, luctus scelerisque velit venenatis. Duis vestibulum justo porta justo pellentesque, ac accumsan diam varius. Ut urna orci, lobortis quis eros sed, accumsan blandit nulla. Integer at arcu euismod, ullamcorper arcu ac, molestie tortor. Aliquam erat volutpat. Nulla iaculis orci neque, vel consequat metus laoreet sed. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut nec porttitor velit, ut elementum tellus.

Quisque dictum enim in quam venenatis, vitae fringilla massa hendrerit. Donec at dapibus elit. Integer id mauris risus. Phasellus lobortis lorem sit amet sem facilisis, et cursus dolor lobortis. Curabitur vehicula placerat enim, vitae cursus arcu mattis ut. Morbi ullamcorper erat sed mauris dapibus dapibus. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Donec sollicitudin sem vel elit convallis blandit. Proin maximus, eros eget condimentum porta, turpis nunc dapibus nisl, eu ornare mi ipsum nec lacus. Maecenas non lectus quis elit placerat dapibus sit amet vitae purus. Nam orci dolor, vulputate a placerat sed, pulvinar at tellus. Praesent nec sapien luctus, faucibus est quis, tincidunt dolor. Pellentesque eu lorem nec tellus blandit varius. Etiam efficitur finibus nisl in molestie.

0
+
PATIENTS SIGNED UP
0
COUNTRIES
0
M €
EU FUNDING
0
SOLUTIONS

CLINICAL TRIALS

ONCO CTC: CTCs as epithelial cancer cells are able to move, migrate and invade blood vessels after epithelialmesenchymal transition (EMT) and have been characterized as the main causal factor of tumor metastasis mediation. Compared to other cancer biomarkers, CTCs contain molecular and biological information about the tumor as a whole, supporting single cell analysis and ongoing changes in tumors at all stages. CTCs can be found in blood as independent cells, and clusters of both CTCs alone and cells aggregates comprising of neutrophils, platelets, and CTCs. Thus, blood-based analysis of CTCs could therefore function as a “liquid biopsy,” allowing repeated sampling.

ONCO NMR: The method has been utilized extensively in other cancer settings, in particular for breast cancer, and recently also for colorectal cancer where the specificity and sensitivity were between 82 to 85%. (Vignoli et al., 2021). UzL has developed a standardized NMR test for the analysis of blood serum and plasma samples.

ONCO CRISPER: The ONCO-CRISP is a screening test based on CRISPR-Cas9 biomarkers. The ONCO-CRISPR tool and human CRISPR microRNAs will enable the detection of clinically relevant biomarkers in colorectal adenomas, colorectal carcinomas in tissue and non- or minimal invasive obtained patient samples. The test consists of a detection dipstick, a reporter, a Cas protein (nuclease, DNA/RNA cutting enzyme) and a guiding RNA, input material that could be RNA or DNA that contains the biomarker of interest, and more. The test will show a negative or a positive result on a used test strip. Testing will be done according to the testing instructions.

ONCO VOC: The ONCO-VOC is a screening test based on Volatile Organic Compounds (VOC). ONCO VOC, The innovative breath analyzer developed by TECHNION, is based on an 8-sensor array of nanomaterials in conjugation with AI. To perform the test a short-exhaled breath sample (2-3sec.) will be evaluated in less than 2 minutes. The results of this test will give an early indication for distinguishing between CRC-linked and healthy categories.

Patient Portal Map

Patient Portal Map
PORTUGAL BULGARIA LITHUANIA GERMANY HUNGARY GREECE ROMANIA

PORTUGAL

IPO PORTO

Contact Person: Luis Carlos Lima

Clinical Trials: ONCO CTC, NMR, and CRISPR

BULGARIA

University Specialized Hospital for Active Treatment of Oncology

Contact Person: Dr. Bojidar Tomov

Clinical Trials: ONCO VOC, ONCO NMR, ONCO CRISPR

-------------------------------

Military Medical Academy Sofia

Contact Person: Dr. Daniela Stoyanova

Clinical Trials: ONCO VOC, ONCO NMR, ONCO CRISPR

LITHUANIA

LSMU Lithuania

Contact Person: Egidijus Morkūnas

Clinical Trials: ONCO NMR and CRISPR

GERMANY

UMC MAINZ

Contact Persons: Markus Moehler ; Katja Petrowski

Clinical Trials: ONCO VOC, NMR, and CRISPR

------------------------------

Lübeck UKSH

Contact Person: Birgitta Spitzner

Clinical Trials: ONCO VOC, NMR, and CRISPR

HUNGARY

University of Szeged

Contact Person: Prof. Dr. Tamás Molnár DSc

Clinical Trials: ONCO NMR and CRISPR

----------------------------

Semmelweis University

Contact Person: Dr. ILIÁS Ákos, PhD

Clinical Trials: ONCO NMR and CRISPR

GREECE

AHEPA University Hospital

Contact Person: Dr. Antonis Billis

Clinical Trials: ONCO VOC, NMR, and CRISPR

ROMANIA

IOB Romania

Contact Person: Geanina Papuc

Clinical Trials: ONCO NMR and CRISPR

CONTACT YOUR NEAREST TRIAL SITE

IPO Porto

IPO Porto

Contact Person:

Luis Carlos Lima

Clinical Trials:

ONCO CTC, NMR, and CRISPR

UMC Mainz

UMC Mainz

Contact Persons:

Markus Moehler

Katja Petrowski

Clinical Trials:

ONCO VOC, NMR, and CRISPR

Lübeck UKSH

Lübeck UKSH

Contact Person:

Birgitta Spitzner

Clinical Trials:

ONCO VOC, NMR, and CRISPR

LSMU Lithuania

LSMU Lithuania

Contact Person:

Egidijus Morkūnas

Clinical Trials:

ONCO NMR and CRISPR

IOB Romania

IOB Romania

Contact Person:

Geanina Papuc

Clinical Trials:

ONCO NMR and CRISPR

Rosenbaum Group

Specialized Hospital for Active Treatment of Oncology

University Specialized Hospital for Active Treatment of Oncology

Contact Person:

Dr. Bojidar Tomov

Clinical Trials:

ONCO VOC, ONCO NMR, ONCO CRISPR

Military Medical Academy Sofia

Military Medical Academy Sofia

Contact Persons:

Dr. Daniela Stoyanova

Clinical Trials:

ONCO VOC, ONCO NMR, ONCO CRISPR

AHEPA University Hospital

AHEPA University Hospital

Contact Person:

Dr. Antonis Billis

Clinical Trials:

ONCO VOC, NMR, and CRISPR

University of Szeged

University of Szeged

Contact Person:

Prof. Dr. Tamás Molnár DSc

Clinical Trials:

ONCO NMR and CRISPR

Semmelweis University

Semmelweis University

Contact Person:

Dr. ILIÁS Ákos, PhD

Clinical Trials:

ONCO NMR and CRISPR

Want to learn More?


LATEST IN ONCOSCREEN

Newsletter Signup

To keep up-to-date with the latest developments in the ONCOSCREEN project, subscribe to our LinkedIn newsletter.

You can always unsubscribe at a later time if you change your mind.